Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia
暂无分享,去创建一个
Stephen L. George | Edward J. Lee | S. George | R. Dodge | R. Stone | Joseph O. Moore | C. Schiffer | B. Powell | Richard Stone | Charles A. Schiffer | Bayard L. Powell | Philip Schulman | Deborah T. Berg | Richard K. Dodge | Paolo Alberto Paciucci | P. Paciucci | P. Schulman | D. Berg | J. Moore
[1] E. Estey. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. , 1994, Blood.
[2] H. Tilly,et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Gray,et al. PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.
[4] H. Gralnick,et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.
[5] E. Vellenga,et al. Acute Myeloblastic Leukemia , 1996 .
[6] C. Begg. Methodological issues in studies of the treatment, diagnosis, and etiology of prostate cancer. , 1994, Seminars in oncology.
[7] C. Bloomfield,et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. , 1994, Cancer genetics and cytogenetics.
[8] Douglas G. Altman,et al. Practical statistics for medical research , 1990 .
[9] H. Preisler. Failure of remission induction in acute myelocytic leukemia. , 1978, Medical and pediatric oncology.
[10] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[11] L. Zwelling,et al. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia , 1993 .
[12] W. Dalton,et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Cannistra. Growth regulation of malignant clonogenic cells in acute myeloid leukemia , 1991, Current opinion in oncology.
[14] C. Bloomfield,et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Pocock,et al. Clinical Trials: A Practical Approach , 1984 .
[16] W. Hiddemann,et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. , 1991, Blood.
[17] B. Löwenberg,et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Kris,et al. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .
[19] Varying intensity of postremission therapy in acute myeloid leukemia. , 1992 .
[20] I. Touw,et al. Hematopoietic growth factors and their receptors in acute leukemia. , 1993, Blood.
[21] E. Estey,et al. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. , 1992, Blood.
[22] R. Bast,et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. , 1988, The New England journal of medicine.
[23] Nitin R. Patel,et al. A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .
[24] J. Fleiss. Statistical methods for rates and proportions , 1974 .
[25] M. Minden,et al. The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. , 1987, Blood.
[26] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[27] Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. , 1986 .
[28] S. Larsen,et al. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. , 1990, Blood.
[29] R. Mayer,et al. The approach to the elderly patient with acute myeloid leukemia. , 1993, Hematology/oncology clinics of North America.
[30] S. Nimer,et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. , 1992, Blood.
[31] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[32] N. Vogelzang,et al. A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. , 1993, JAMA.
[33] W. Grove. Statistical Methods for Rates and Proportions, 2nd ed , 1981 .
[34] Ron Brookmeyer,et al. A Confidence Interval for the Median Survival Time , 1982 .
[35] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[36] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.